Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—Based on a hospital study in China

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

“…Since its publication, 14 studies worldwide (Data Supplement) have validated the clinical relevance of this new classification system. These studies have confirmed a 100% survival outcome of adenocarcinomainsituwith100%LEPgrowthpattern 5,6,8,[16][17][18][19][20][21] andconsistently reported that the worst survival outcomes were seen in patients with invasive adenocarcinoma with predominately MIP and SOL patterns (Data Supplement).…”

The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status

“…Th e main interest of this new classifi cation was its prognostic impact as reported by several studies. [5][6][7][8][9][10][11][12] Yoshizawa et al 10 identifi ed three groups of tumors with diff erent survival in stage I cancer: low grade with AIS and MIA (100% 5-year disease-free survival); intermediate grade with nonmucinous lepidic predominant, papillary predominant, and acinar predominant (90%, 83%, and 84% 5-year disease-free survival, respectively); and high grade with invasive mucinous adenocarcinoma, solid and micropapillary predominant (75%, 70%, and 67% 5-year disease-free survival, respectively). Interestingly, histologic grade frequency is heterogeneous, especially for AIS and MIA tumors, as underlined by two reports, one concerning 500 white patients with neither AIS nor MIA subtypes 8 and another study on 440 Asian patients reporting 12% of AIS and MIA.…”

Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?

“…In these series, lower grade tumours (such as lepidic predominant) have been shown to be associated with a lower risk for recurrence, while those with higher grade tumours (such as micropapillary, invasive mucinous adenocarcinoma and solid predominant tumours) had worse disease-free and overall survival [9]. This prognostic ability remains significant in multivariate analyses that include factors such as age, stage and resection margin status, among other covariates, acting as an independent predictor of disease-free and overall survival [6,[10][11][12]. However, in some series, its prognostic ability has been weaker [13].…”